Psychedelic-assisted Therapy in Practice – Swiss Landscape

Abstract

The integration of Psychedelic-assisted Therapy (PAT) into psychotherapy may present new opportunities for treating mental disorders, with Swiss experiences potentially influencing global PAT practices: In Switzerland, since 2014, the substances LSD, MDMA, and psilocybin have been used therapeutically under exemption permits issued by the Swiss Federal Office for Public Health. Over the past ten years, these permits have facilitated more than 1000 individual case authorizations, leading to an estimated 2000–3000 treatments conducted by approximately 60 therapists. The evolving nature of PAT in Switzerland brings new challenges, particularly due to the rising interest in these therapies. 

This presentation aims to provide an overview of the current PAT landscape in Switzerland. We will discuss the legal framework, practical aspects, and address treatment recommendations based on clinical expertise of practitioners. Implications of these practices and potential future directions for PAT both in Switzerland and internationally will be explored.

Biography

Helena works as a psychotherapist, incorporating limited medical use of psychedelics in private practice and at the Psychiatric University Hospital Zurich. As a postdoctoral researcher (University of Zurich), she is involved in clinical trials using DMT/harmine and 5-MeO-DMT, and also coordinates a study on therapists' personal psychedelic experiences (University of Basel). Helena is involved in the SÄPT, especially in the training of therapists, aiming to bridge science and practice.

Through her diverse roles, Helena remains dedicated to advancing the field of psychedelic therapy, integrating scientific research with clinical practice to improve therapeutic interventions and training for future therapists.